|
|
||||||||
Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland 21201
| |
ABSTRACT |
|---|
|
|
|---|
Cultured COS-1 cells, as well as chicken
embryonic and neonatal rat cardiac myocytes, were infected with
recombinant adenovirus vectors to define limiting factors in the
expression and Ca2+ transport
function of recombinant sarcoplasmic-endoplasmic reticulum Ca2+ (SERCA) isoforms. Titration
experiments showed that all COS-1 cells and myocytes in culture could
be infected by an adenovirus titer of 10 plaque-forming units (pfu) per
seeded cell. Raising the adenovirus titer further yielded higher
protein expression up to an asymptotic limit for functional,
membrane-bound SERCA protein. The asymptotic behavior of SERCA
expression was not transcription related but was due to
posttranscriptional events. The minimal (
268) cardiac troponin T
(cTnT) promoter was a convenient size for adenovirus vector
construction and manifested tight muscle specificity. However, its
efficiency was lower than that of the nonspecific cytomegalovirus (CMV)
promoter. At any rate, identical maximal levels of SERCA expression
were obtained with the CMV and the cTnT promoter, as long as the viral
titer was adjusted to compensate for transcription efficiency. A
maximal threefold increase of total SERCA protein expression over the
level of the endogenous SERCA of control myocytes was reached (a
sevenfold increase compared with the endogenous SERCA of the same
infected myocytes due to reduction of endogenous SERCA after
infection). In contrast with previous reports [Ji et al.
Am. J. Physiol. 276 (Heart Circ. Physiol. 45):
H89-H97, 1999], a higher kinetic turnover was demonstrated
for the SERCA1 compared with the SERCA2a isoform as shown by a 5.0- versus 2.6-fold increase in calcium uptake rate accompanying maximal
expression of recombinant SERCA1 or SERCA2a, respectively. This
information is deemed necessary for studies attempting to modify
myocardial cell function by manipulation of SERCA expression.
calcium adenosine 5'-triphosphatase; sarcoplasmic-endoplasmic reticulum calcium; adenovirus vectors
| |
INTRODUCTION |
|---|
|
|
|---|
THE SARCOPLASMIC-ENDOPLASMIC RETICULUM CALCIUM (SERCA) ATPase plays an important role in storing intracellular Ca2+ and regulating cytosolic Ca2+ concentration. A number of cell functions, including muscle contraction and relaxation, are thereby dependent on the activity of this enzyme in situ. Furthermore, defects of SERCA expression and intracellular Ca2+ homeostasis appear to be associated with pathological states of cardiac muscle (12, 26, 28).
Various SERCA isoforms and gene-splicing products have been cloned (2, 23), including SERCA1, which is the isoform expressed specifically in skeletal muscle (2), and SERCA2a, which is prevalently expressed in cardiac muscle (35). Subsequently, SERCA cDNA constructs have been used for heterologous expression in COS-1 cells and in cardiac muscle to perform mutational analysis of recombinant enzyme (25) or used to study the influence of SERCA overexpression on cell functions (7, 9, 10, 13, 15, 16, 22). It is not yet clear, however, whether the yield of heterologous SERCA in cardiac myocytes is subjected to limits of transfection efficiency, transcription, translation, and functional folding of the expressed protein. Furthermore, the efficiencies and cell specificities of various promoters in cardiac myocytes are not yet defined. Finally, a detailed characterization of the two isoforms with regard to heterologous expression and comparative functional behavior is not available. Yet, all of this information is necessary if attempts are to be made to influence Ca2+ homeostasis and related functions by manipulation of SERCA expression in cardiac myocytes.
We describe in this paper a series of studies on heterologous expression of SERCA1 and SERCA2a isoforms in COS-1 cells and in chicken embryonic and neonatal rat cardiac myocytes, providing a systematic characterization of gene transfer procedures, effects of promoters, limits of protein expression, and comparative features of the recombinant SERCA1 and SERCA2a isoforms.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
DNA constructs and vectors. Enhanced green fluorescence protein (EGFP) and chicken (17) or rabbit SERCA1 (23) or SERCA2a (4, 35) cDNA were subcloned into the shuttle plasmid pdE1sp1A (Microbix Systems), preceded by various promoters and followed by SV40 polyadenylation signal. Shuttle plasmids were used for transfection of HEK-293 cells in conjunction with the replication-defective viral DNA plasmid pJM17 (Microbix Systems) to obtain recombinant adenovirus (8).
Alternatively, analogous shuttles were constructed utilizing the plasmid pAdlox. These shuttle plasmids were used for transfection of CRE8 cells in conjunction with the replication-defective adenovirus psi5, to obtain recombinant adenovirus vectors according to the methods of Hardy et al. (11).
In either case, the shuttle plasmids were constructed such that homologous recombination resulted in antisense direction of the gene of interest with respect to the adenovirus E1 gene promoter. The recombinant products were selected by repetitive replications in HEK-293 or CRE8 cells and band purified by centrifugation in cesium chloride gradients to yield concentrations of the order of 106-107 plaque-forming units (pfu)/µl.
Cell cultures. Cultures of HEK-293 cells, CRE8 cells, and COS-1 cells were maintained as described by Graham and Prevec (8), Hardy et al. (11), and Sumbilla et al. (31), respectively.
Primary cell cultures of cardiac myocytes and skin fibroblasts were obtained from day 8 chicken embryos as previously described (15). Rat neonatal cardiac myocyte cultures were prepared as described in Kariya et al. (18).
Infections of cultured cells with recombinant adenovirus vectors were performed with 0.5-20 pfu/seeded cell in serum-free medium. Ninety minutes thereafter, the infection medium was diluted fourfold with culture medium containing 100 U of Pen-Strep and 1 µg of Fungizone/ml. Two days after the infection the cells were harvested for microscopic or biochemical tests.
The shuttle plasmids described in DNA constructs and vectors were also utilized as such (without adenovirus recombination) for transfection of cultured cells. In this case transfections were performed by the DEAE-dextran method as described by Sumbilla et al. (31), by utilization of the liposome PerFect kit (Invitrogen), or by the calcium phosphate method described in Kariya et al. (18).
In situ evidence of heterologous expression was obtained by fluorescence microscopy of cell lawns simply rinsed with phosphate-buffered saline (PBS) (in the case of EGFP) or following staining with specific monoclonal antibodies and secondary fluorescent antibodies (in the case of the SERCA isoforms) as described by Inesi et al. (15).
Cell harvesting and protein analysis.
Cell lawns were rinsed with cold PBS, and a cold suspension medium (10 ml per 100-mm dish) containing 50 mM
3-(N-morpholino)propanesulfonic acid (MOPS), pH 7.0, 10 mM
NaF, 1 mM EDTA, 0.3 M sucrose, 0.5 mM dithiothreitol, 0.4 mM Pefabloc,
10 µg/ml aprotinin, 1 µg/ml pepstatin A, and 2 µg/ml leupeptin
was added. The cells were collected by scraping with a
spatula, and the resulting suspension was centrifuged at 2,000 g for 2 min. The sedimented cells were
then resuspended in 1 ml of the same medium, frozen in liquid nitrogen,
and stored at
70°C. Within 2 wk of storage the frozen cells
were thawed and homogenized with 100 strokes of a hand-held homogenizer
immediately before use for functional tests (see
Functional studies). In
some cases, COS-1 cells were homogenized and subjected to differential centrifugation for preparation of microsomes as described by Strock et
al. (30).
Total protein was determined either by direct reading of 280-nm light absorbance following solubilization in 1% sodium dodecyl sulfate or by the bicinchoninic acid assay (Pierce) following sonication. Protein electrophoretic analysis was performed in 7.5% acrylamide gels according to Laemmli (20) and staining with Coomassie Blue. For Western blots the proteins were transferred onto nitrocellulose paper and stained with primary monoclonal and secondary (goat anti-mouse IgG-horseradish peroxidase conjugated) antibodies. The monoclonal antibodies (Affinity Bioreagents) were either specific for SERCA1 or SERCA2a protein or reactive to a common c-myc tag linked to the COOH terminal of both isoforms. Monoclonal antibodies were also used for detection of calsequestrin and phospholamban. The reactive bands were visualized using an enhanced chemiluminescence-linked detection system (Amersham Pharmacia Biotech), and their density was quantitated with the aid of a NucleoTech work station and Gel Expert software.
Northern blots. Total RNA was extracted by aspirating the medium from cell culture dishes, adding 0.3-0.4 ml of TRIzol LS (GIBCO-BRL) per 10 cm2 cell lawn, and following the GIBCO-BRL procedure. The final RNA pellet was dissolved in diethyl pyrocarbonate-water (Quality Biological) to yield ~1 mg RNA/ml. The final yield was 50 µg of total RNA from one 150-mm dish.
Electrophoresis and blotting were performed by the use of the Northern Max-Gly Blotting Kit from Ambion. mRNA detection was obtained with a DIG High Prime Labeling and Detection kit from Boehringer Mannheim. SERCA1 cDNA was used as a template for the probe.
Functional studies. ATP-dependent Ca2+ transport was measured in a reaction mixture containing 40 mM MOPS (pH 7.0), 100 mM KCl, 5.0 mM MgCl2, 5.0 mM NaN3, 0.2 mM EGTA, 1 µM ruthenium red, 0.2 mM [45Ca]CaCl2, and cell lysate (30-60 µg/ml) or microsomal (5-10 µg/ml) protein. The reaction was started by the addition of 5.0 mM potassium oxalate, and after 2 min, 5.0 mM ATP was added at 37°C. Samples were collected before and, at serial times, after the addition of ATP. The samples (1 ml each) were passed through 0.45-µm Millipore filters, which were then washed with 2.0 mM LaCl3 in 10 mM MOPS (pH 7.0), blotted, and used for determination of radioactive calcium by scintillation counting.
ATPase activity was measured in a reaction mixture containing 20 mM MOPS (pH 7.0), 80 mM KCl, 3.0 mM MgCl2, 5.0 mM NaN3, 0.2 mM EGTA, 0.2 mM CaCl2, 3 µM calcium ionophore A-23187, and 30-100 µg/ml cell lysate or microsomal protein. The reaction was started by the addition of 3.0 mM ATP at 37°C. Serial samples were collected before and after addition of ATP. Pi was determined according to Lanzetta et al. (21).
Phosphoenzyme decay rates were determined by first obtaining steady-state levels of radioactive phosphorylated enzyme intermediate by adding 0.1 ml of 10 µM [32P]ATP to 0.4 ml of a reaction mixture containing 20 mM MOPS (pH 7.0), 80 mM KCl, 5.0 mM MgCl2, 0.1 mM CaCl2, and 30-100 µg of microsomal protein. The components of the reaction mixture were preincubated in ice, and vortex mixing was carried out in the cold room. Ten seconds after the addition of radioactive ATP, a pulse chase of 0.5 ml of 1.0 mM nonradioactive ATP was added with rapid mixing, and samples were quenched at various times by adding 0.4 ml of 4 M perchloric acid. Two zero-time samples were obtained by quenching before the addition of nonradioactive ATP. The quenched samples were transferred onto Eppendorf tubes containing 100 µg of carrier protein and centrifuged at 5,000 rpm for 5-10 min. The sediment was washed twice with 0.125 M perchloric acid and once with water. The entire procedure was carried out in ice and in the cold room. Aliquots of the solubilized samples were subjected to electrophoresis (34) at pH 6.3, and the radioactive phosphoenzyme was detected by autoradiography and phosphoimaging.
| |
RESULTS |
|---|
|
|
|---|
Efficiency of gene transfer in cultured
cells. It is known that expression in COS-1 cells is
enhanced if the exogenous gene is placed under control of the SV40
promoter. This enhancement is due to amplification of the transfected
plasmid, triggered by SV40 promoter interaction with T-antigen in the
COS-1 cells. The overall protein expression in cell cultures, however,
is limited drastically by the small percentage (2-5%) of cells
effectively transfected by procedures based on the use of calcium
phosphate, DEAE-dextran, or liposomes. This limit can be overcome by
the use of recombinant adenovirus vectors, which allow effective
transfection of nearly 100% of the COS-1 cells in culture. We found,
however, that complementation of the SV40 promoter with the COS-1 cell T antigen does not trigger amplification of the recombinant gene caused
by limits imposed by the viral DNA. Therefore, heterologous protein
expression is highly dependent on the strength of the promoter. For
these reasons the highest overall level of expression in cell cultures
is obtained by placing the cDNA under control of the cytomegalovirus
(CMV) promoter and using recombinant adenovirus vectors. Thereby, high
percentages of transfected cells, as well as high levels of expression
in each cell, are obtained in both COS-1 cells and chicken embryonic
cardiac myocytes (Fig. 1). High expression
levels were also obtained with neonatal rat cardiac myocytes (results
not shown).
|
In experiments with adenovirus vectors, an important variable is the
number of viral particles (pfu) per infected cell. We defined this
variable in our experiments by exposing either COS-1 cells or cardiac
myocytes to increasing titers of recombinant adenovirus vector carrying
the EGFP DNA-coding sequence under control of the CMV promoter. In
these experiments the percentage of cells expressing EGFP was
conveniently determined by simply comparing phase and fluorescent
microscopic views of the cells in culture. It should be pointed out
that determinations of plaque-forming units per cell ratios are
approximate, because their accuracy is limited by various
uncertainties, including the degree of cell proliferation within the
time interval (i.e., 2 days) intervening between cell infections and
harvesting. It can be safely concluded, however, that nearly 100% of
both COS-1 cells and myocytes produce EGFP following exposure to
10-20 pfu per seeded cell (Fig. 2). Similar results were obtained when the adenovirus vector carried the
SERCA DNA-coding sequence and SERCA ATPase expression was visualized by
immunostaining and fluorescence microscopy (15).
|
Overall expression of EGFP and SERCA
ATPase. We found that overall protein expression was
further increased when the plaque-forming unit level was raised above
levels affecting 100% of the cells in culture (i.e., 10-20
pfu/cell). In fact, in experiments with either COS-1 cells or myocytes,
EGFP expression was linearly related to the viral titer (Fig.
3), demonstrating dependence not only on
the number of transfected cells but also on the number of foreign gene
copies in each cell.
|
As opposed to EGFP, expression of SERCA ATPase was not linearly related
to the plaque-forming unit level but appeared to reach an asymptote
both in myocytes and in COS-1 cells as revealed by the Western blot
densities plotted in Fig. 3. It is of interest that Northern blots of
samples obtained under the same conditions from either COS-1 cells or
cardiac myocytes show that the SERCA mRNA levels continue to increase
as the plaque-forming unit titer is raised above the asymptotic limit
of SERCA protein expression (compare Fig. 4
with Fig. 3). Therefore, in our experiments, the asymptotic behavior of
SERCA protein expression at high plaque-forming unit levels is not due
to a transcriptional limit.
|
Promoter efficiency and specificity.
We have previously obtained expression of functional SERCA1 protein in
cultured chicken embryonic myocytes infected with recombinant
adenovirus vector carrying the SERCA1 DNA-coding sequence under control
of either a viral (SV40) promoter or the cTnT muscle-specific promoter
(15). In most of the experiments reported here we have used the highly active CMV promoter. We also performed comparative experiments with the
cTnT minimal promoter (
268), a more extended segment of the cTnT
promoter, including its homologous enhancer (
550) and a chimeric
construct of the CMV enhancer with the cTnT minimal promoter (Fig.
5). To eliminate comparative artifacts
possibly related to inaccurate plaque-forming unit levels of various
recombinant adenovirus preparations, these experiments were performed
by liposome-assisted transfections, using EGFP cDNA subcloned in the
same plasmids but under control of various promoter constructs. The
comparative levels of EGFP expressed in cardiac myocytes and
fibroblasts are shown in Table 1. The
greatest difference is between the CMV and the cTnT minimal promoter
(
268), with the former being more active but displaying no cell
specificity and the latter being weaker but totally muscle specific.
|
|
The activity of the
268 cTnT promoter can be increased eightfold
by the presence of the CMV enhancer but with significant loss of cell
specificity (Table 1 and Fig. 6). The CMV
enhancer, by itself, yields no protein expression. It is noteworthy
that the chicken cTnT promoter is just as effective in rat neonatal myocytes (Table 1) as it is in chicken embryonic myocytes. In fact, the
extended
550 cTnT promoter is two to three times more active
than the
268 minimal promoter in rat neonatal myocyte and yet
retains total cell specificity.
|
It is of interest to note that despite the different efficiencies of
the CMV and of the minimal (
268) cTnT promoter, the same maximal
level of SERCA1 ATPase expression can be obtained in cardiac myocytes
under control of either promoter. This can be accomplished by
increasing the plaque-forming unit levels of adenovirus vector
containing the weaker promoter to obtain the asymptotic level of
protein expression by the myocytes (Fig.
7). When we compared the total SERCA
protein (either isoform) level obtained under these conditions, we
found them to be approximately threefold higher than the levels of
endogenous SERCA2a of control myocytes. It should be pointed out that
strong heterologous SERCA expression inhibits significantly the
expression of endogenous SERCA2a (15, 22). For this reason, the high
levels observed in infected cells actually display a ratio of ~7:1
for heterologous to (residual) endogenous SERCA.
|
SERCA1 and SERCA2a isoforms. The
advantage of the CMV promoter is that high levels of expression can be
obtained with relatively low adenovirus plaque-forming unit levels. In
fact, we were able to obtain levels of SERCA1 and SERCA2a expression
that could be demonstrated by simple staining of electrophoretic gels
with Coomassie Blue (Fig. 8). Protein
staining provided a very convenient method for comparative evaluation
of SERCA isoform expression, independent of immunochemical reactions
with antibodies that may be unequally reactive to various isoforms
derived from different animal species. It should be pointed out that
comparative evaluation of SERCA expression by protein staining or
immunochemical detection of the same antigenic tag yielded identical
results. We were then able to compare the activities of microsomes
obtained from COS-1 cells infected with vectors carrying SERCA1 or the
SERCA2a cDNA. The COS-1 expression system is very well suited for this
comparison, because noninfected COS-1 cells sustain negligible SERCA
activity. We then found that when the
Ca2+ uptake and ATPase activity of
infected cells were related to the levels of expressed enzymes (as
revealed by electrophoresis and protein stain or by immunodetection of
an identical antigenic tag), the SERCA1 isoforms appeared to sustain
approximately twofold higher rates than the SERCA2a isoforms (Fig.
9).
|
|
The functional rates given in Fig. 9 are heavily dependent on the
amount of recombinant SERCA per total microsomal protein, as revealed
by electrophoresis. To eliminate the possible interference of
inaccurate SERCA protein determinations, we then performed a series of
experiments in which the turnover of the recombinant enzymes was
determined by pulse chase. In these experiments we first allowed the
enzyme to reach steady-state levels of radioactive phosphorylated
enzyme intermediate by incubation with
[32P]ATP and then
added excess nonradioactive ATP so that hydrolytic cleavage of the
radioactive intermediate would be followed by formation of
nonradioactive intermediate. Under these conditions, the radioactive
intermediate undergoes exponential decay with a rate constant that is
representative of the enzyme turnover and is independent of the enzyme
concentration. It is shown in Fig. 10
that the SERCA1 turnover is approximately two times faster than the
SERCA2a turnover. In fact, the average rate constants were 0.26 and
0.14 s
1 for the chicken
SERCA1 and SERCA2a, respectively, and 0.31 and 0.12 s
1 for the rabbit
SERCA1 and SERCA2a. This is in contrast with previous reports (Ref. 16;
see DISCUSSION).
|
To obtain a further comparison of SERCA1 and SERCA2a functions, we
infected myocytes with increasing plaque-forming unit titers of
adenovirus vectors carrying either SERCA1 or SERCA2a cDNA. We found
that the asymptotic levels of function, corresponding to maximal
expression, were approximately two times higher for the SERCA1 than for
the SERCA2a ATPase (Fig. 11). This is
again consistent with a higher turnover of the SERCA1 isoform and
demonstrates that, under conditions of maximal heterologous SERCA
expression, the calcium transport activity of myocytes can be increased
~5.0- or 2.6-fold, depending on whether SERCA1 or SERCA2a cDNA is
used.
|
Ca2+
concentration dependence of endogenous and heterologous SERCA.
Finally, we investigated whether endogenous and heterologous ATPase
isoforms may be activated by different
Ca2+ concentrations. This
evaluation was obtained by measuring ATP hydrolysis by microsomal
vesicles rendered leaky by the addition of a
Ca2+ ionophore to avoid back
inhibition by accumulated Ca2+ and
allow linear rates of enzyme activity, depending on activation by
Ca2+. It is shown in Fig.
12A that
SERCA1 and SERCA2a expressed in COS-1 cells display an identical
Ca2+ concentration dependence. On
the other hand, the endogenous SERCA2a ATPase of myocytes appears to
have a slightly higher Ca2+
dependence than heterologous SERCA1 (Fig.
12B). The difference is small but
nevertheless consistent with the influence of phospholamban on SERCA
activation by Ca2+, as
demonstrated in adult cardiac muscle by several laboratories (3, 19,
27, 29, 32, 33), including our own (5). These experiments demonstrate
that the different velocities displayed by various isoforms (Figs. 9,
10, and 11) are not due to a different level of activation by the same
concentration of Ca2+ but rather
to intrinsic kinetic properties of each isoform.
|
| |
DISCUSSION |
|---|
|
|
|---|
Regulation of several cell functions, including contraction and relaxation, is dependent on transient changes of the cytosolic Ca2+ concentration, as well as cytosolic Ca2+ sequestration by SERCA ATPases. Therefore, experimental manipulation of SERCA copy numbers is of general interest for possible effects on cell functions. To this aim, development of transgenic animal models (16, 22) is very useful inasmuch as functional consequences of SERCA manipulations can be studied at the whole organ or whole animal level (1). On the other hand, cultured cells provide an opportunity for extensive evaluation of gene transfer techniques, promoter and cDNA constructs, gene copy numbers, and other variations that may be useful in selecting the most suitable conditions for gene transfer. We find that this type of experiment is greatly aided by recombinant adenovirus vectors. These vectors provide a most efficient and convenient method for delivery of DNA constructs to a variety of cells, including cardiac myocytes. Because the recombinant virus is replication defective, its titer can be kept constant and adjusted to introduce a predetermined number of heterologous gene copies in cultured cells, thereby producing controlled expression of recombinant protein. In fact, we demonstrated with our experiments that with an average of 10 pfu per seeded cell, it is possible to infect nearly all COS-1 cells or myocytes in culture (Fig. 2). Further increase in the multiplicity of infection produces a proportionally higher level of expression, evidently due to the higher number of gene copies introduced in each cell.
We find that while the expression level of cytosolic EGFP rises linearly with the adenovirus vector titer up to 20 pfu per seeded cell, the expression level of membrane bound SERCA reaches an asymptote at 10 pfu per seeded cell (Fig. 3). This is true in both COS-1 cells and myocytes, although the maximal SERCA expression in COS-1 cells is somewhat higher than that in myocytes. It is of interest that SERCA mRNA continues to increase as the viral titer is raised (Fig. 4), indicating that the promoters used in our experiments can overcome the limits of endogenous transcription regulation. It is then apparent that posttranscriptional events impose a limit on the level of SERCA expression. These observations explain previous studies on Ca2+-ATPase overexpression in transgenic animals, in which the SERCA2a protein level was found to increase only 1.3- to 1.5-fold, whereas the mRNA level was increased 3.9- to 7.9-fold (1). In our experiments with cardiac myocytes infected with adenovirus vectors, the level of SERCA protein could be raised to a threefold maximum compared with the level of endogenous SERCA in control myocytes. It should be pointed out the heterologous SERCA is sevenfold higher compared with the (residual) endogenous SERCA of the same infected myocytes because of reduction of endogenous SERCA following infection. This rise is higher than obtained in any of the transgenic animal models and defines the maximal level that can be reached by manipulation of SERCA expression.
The choice of a promoter is a cogent question, because one would want a strong as well as cell-specific promoter, to obtain high rates of transcription and yet avoid expression in cells other than myocytes. We found the CMV promoter to be very strong but not at all cell specific. As previously reported (15), the minimal segment of the cTnT promoter (24) can be used for heterologous expression of SERCA ATPase. Its short length (268 bp) and its stringent myocyte specificity are very convenient, although its efficiency is ~10 times lower that that of the CMV promoter (Table 1). At any rate, an important conclusion of our experiments is that it is possible to reach maximal levels of SERCA expression using either the CMV or the cTnT promoter (Fig. 7), if the titer of the adenovirus vector is adjusted to deliver a suitable number of gene copies. As noted above, no further SERCA expression can be obtained when the asymptotic levels of translation and targeting are reached, even in the presence of higher transcriptional pressure.
It should be noted that increasing the length of the
268 bp cTnT
promoter to
550 bp, thereby including homologous enhancing segments (24), raised significantly the strength of the minimal promoter, especially in neonatal rat myocytes. On the other hand, inclusion of the CMV enhancer greatly increased the strength of the
268 cTnT promoter but also caused considerable loss of cell specificity (Table 1 and Fig. 6). This observation is of interest inasmuch as it shows that a nonspecific viral promoter enhancer, which
has no activity of its own, can form a very active transcriptional complex in concomitance with the minimal cardiac promoter, evidently interacting with constitutive cardiac factors. The other observation of
interest is that the chicken cTnT promoter is active in rat as well as
in chicken myocytes.
Comparative kinetic definition of the skeletal and cardiac SERCA isoforms has been a problem since early studies (14) showed that sacroplasmic reticulum (SR) vesicles isolated from cardiac muscle were less active than SR vesicles isolated from skeletal muscle. Even though better SR preparations were later obtained, we were left with the impression that isolation of SR vesicles from cardiac muscle produces more protein degradation and more contaminants than isolation from skeletal muscle and, for this reason, the cardiac vesicles seem less active. However, the more recently acquired possibility of expressing SERCA protein by transfection of COS-1 cells (25) allows us to obtain the two isoforms from the same source, thereby permitting a more rigorous comparison of their kinetic features. Our experiments demonstrate that SERCA2a turnover is approximately one-half as fast as that of the SERCA1 enzyme. This was demonstrated by comparing the steady-state velocity of preparations of which SERCA1 and SERCA2a contents were determined by the use of a common immunogenic tag or by protein stain of electrophoretic gels (Figs. 8 and 9). The turnover of the two isoforms was also evaluated by comparing the exponential (thereby concentration independent) decay of the phosphorylated enzyme intermediate (Fig. 10) and found to be twice as fast for the SERCA1 isoform. This is in contrast with the identical phosphoenzyme decay reported for endogenous SERCA2a and heterologous SERCA1 in transgenic animals (16). It should be noted, however, that these transgenic animals exhibited only a 1.8-fold increase in Ca2+ uptake activity, relative to controls, and the kinetic measurements included a high component related to endogenous SERCA2a. On the other hand, we measured phosphoenzyme decay of SERCA1 and SERCA2a isoforms expressed separately by COS-1 cells, which do not have significant levels of endogenous SERCA activity. Furthermore, we repeated these measurements with both chicken and rabbit SERCA isoforms to avoid ambiguities that may be related to species differences.
Experiments with cultured myocytes (9, 10) as well as with transgenic animals (7, 13, 16, 22) have already demonstrated that heterologous expression of the SERCA1 skeletal muscle isoform can be obtained in cardiac muscle, thereby contributing to sequestration of Ca2+ involved in excitation-contraction coupling. In this regard we find that if expression of either isoform is obtained at maximal level by suitable adjustment of the adenovirus vector titer, the resulting Ca2+ transport activity is approximately two times higher in myocytes transfected with SERCA1 cDNA than in myocytes transfected with SERCA2a cDNA (Fig. 11). Therefore, under conditions permitting maximal (and nearly identical) levels of either SERCA1 or SERCA2a heterologous expression, the resulting increase in calcium transport activity is 5.0- or 2.6-fold, depending on whether the expressed isoform is SERCA1 or SERCA2a. This defines the maximal increment of Ca2+ transport activity that can be obtained in myocytes by expression of heterologous SERCA.
Finally, we find that the SERCA1 and SERCA2a isoforms expressed in COS-1 cells display an identical Ca2+ concentration dependence. COS-1 cells do not contain significant levels of endogenous SERCA or phospholamban; therefore, they are well suited to comparative experiments on the Ca2+ dependence of the two isoforms. On the other hand, cardiac myocytes contain significant levels of endogenous SERCA2a, which requires a slightly higher Ca2+ for activation (Fig. 12B), likely due to regulation by phospholamban. The important point is that, at least in our experiments with embryonic myocytes, neither heterologous SERCA1 nor SERCA2a appears to acquire regulation by phospholamban, because it would be revealed by a displacement of the Ca2+ activation curve. It should be pointed out that Ji et al. (16) found evidence of SERCA1 regulation in the heart of adult transgenic animals. They also found, however, that phospholamban expression was not increased in the same transgenic hearts (22). It is possible that the native SR content of endogenous phospholamban was sufficient to interact with the rather modest level of SERCA1 expression in those transgenic animals. In our experiments we also found no increase in either phospholamban or calsequestrin expression (results not shown).
In conclusion, we obtained basic information on effective methods for SERCA gene transfer in cultured COS-1 cells and cardiac myocytes, choice of promoters for efficient and cell-specific transcription, limits of maximal expression, functional competence of the expressed protein, and comparative evaluation of cardiac and skeletal isoforms. This information is a basic prerequisite for modification of cell function by gene transfer in experimental studies or possible therapeutic interventions. Further studies are required to apply the information obtained with embryonic and neonatal myocytes to adult cardiac muscle.
| |
ACKNOWLEDGEMENTS |
|---|
The authors are very grateful to Drs. Douglas Fambrough (Johns Hopkins University), David MacLennan (University of Toronto), and Charles Ordahl (University of California, San Francisco) for generous gifts of cDNA clones. Manuscript and figures were edited by Jerry Domanico.
| |
FOOTNOTES |
|---|
This research was supported by National Heart, Lung, and Blood Institute Grant PO1 HL-27867.
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests and other correspondence: G. Inesi, Dept. of Biochemistry and Molecular Biology, UMB, 108 N. Greene St., Baltimore, MD 21201 (E-mail: ginesi{at}umaryland.edu).
Received 8 June 1999; accepted in final form 23 July 1999.
| |
REFERENCES |
|---|
|
|
|---|
1.
Baker, D. L.,
K. Hashimoto,
I. L. Grupp,
Y. Ji,
T. Reed,
E. Loukianov,
G. Grupp,
A. Bhagwhat,
B. Hoit,
R. Walsh,
E. Marban,
and
M. Periasamy.
Targeted overexpression of the sarcoplasmic reticulum Ca2+-ATPase increases cardiac contractility in transgenic mouse hearts.
Circ. Res.
83:
1205-1214,
1998
2.
Brandl, C. J.,
N. M. Green,
B. Korczak,
and
D. H. MacLennan.
Two Ca2+-ATPase genes: homologies and mechanistic implications of deduced amino acid sequences.
Cell
44:
597-607,
1986[Medline].
3.
Briggs, F. N.,
K. F. Lee,
A. W. Wechsler,
and
L. R. Jones.
Phospholamban expressed in slow-twitch and chronically stimulated fast-twitch muscles minimally affects calcium affinity of sarcoplasmic reticulum Ca2+-ATPase.
J. Biol. Chem.
267:
26056-26061,
1992
4.
Campbell, A. M.,
P. D. Kessler,
Y. Sagara,
G. Inesi,
and
D. M. Fambrough.
Nucleotide sequences of avian cardiac and brain SR/ER Ca2+- ATPases and functional comparisons with fast twitch Ca2+-ATPase. Calcium affinities and inhibitor effects.
J. Biol. Chem.
266:
16050-16055,
1991
5.
Cantilina, T.,
Y. Sagara,
G. Inesi,
and
L. R. Jones.
Comparative studies of cardiac and skeletal sarcoplasmic reticulum ATPases.
J. Biol. Chem.
268:
17018-17025,
1993
6.
Fabiato, A.,
and
F. Fabiato.
Calculator programs for computing the composition of the solutions containing multiple metals and ligands used for experiments in skinned muscle cells.
J. Physiol. Paris
75:
463-505,
1979[Medline].
7.
Giordano, F. J.,
H. P. He,
P. McDonough,
M. Meyer,
M. R. Sayen,
and
W. H. Dillmann.
Adenovirus-mediated gene transfer reconstitiutes depressed sarcoplasmic reticulum Ca2+-ATPase levels and shortens prolonged cardiac myocyte Ca2+ transients.
Circulation
96:
400-403,
1997
8.
Graham, F. L.,
and
L. Prevec.
Adenovirus based expression vectors and recombinant vaccines.
In: Vaccines: New Approaches to Immunological Problems, edited by R. W. Ellis. Boston, MA: Butterworth-Heinemann, 1992, p. 363-390.
9.
Hajjar, R. J.,
J. X. Kang,
J. K. Gwathmey,
and
A. Rosenzweig.
Physiological effects of adenoviral gene transfer of sarcoplasmic reticulum calcium ATPase in isolated rat myocytes.
Circulation
95:
423-429,
1997
10.
Hajjar, R. J.,
U. Schmidt,
J. X. Kang,
T. Matsui,
and
A. Rosenzweig.
Adenoviral gene transfer of phospholamban in isolated rat cardiomyocytes: rescue effects by concomitant gene transfer of sarcoplasmic reticulum Ca2+-ATPase.
Circ. Res.
81:
145-153,
1997
11.
Hardy, S.,
M. Kitamura,
T. Harris-Stansil,
Y. Dai,
and
M. L. Phipps.
Construction of adenovirus vectors through Cre-lox recombination.
J. Virol.
71:
1842-1849,
1997[Abstract].
12.
Hasenfuss, G.,
H. Reinecke,
R. Studer,
M. Meyer,
B. Pieske,
J. Holtz,
C. Holubarsch,
H. J. Posival,
and
H. Drexler.
Relation between myocardial function and expression of sarcoplasmic reticulum Ca2+-ATPase in failing and nonfailing human myocardium.
Circ. Res.
75:
434-442,
1994
13.
He, H. P.,
F. J. Giordano,
R. Hilat-Dandan,
D. J. Choi,
H. A. Rockman,
P. M. McDonough,
W. F. Bluhm,
M. Meyer,
M. R. Sayen,
E. Swanson,
and
W. H. Dillmann.
Overexpression of the rat sarcoplasmic reticulum Ca2+ ATPase gene in the heart of transgenic mice accelerates calcium transients and cardiac relaxation.
J. Clin. Invest.
100:
380-389,
1997[Medline].
14.
Inesi, G.,
S. Ebashi,
and
T. Watanabe.
Preparation of vesicular relaxing factor from bovine heart tissue.
Am. J. Physiol.
14:
167-222,
1964.
15.
Inesi, G.,
D. Lewis,
C. Sumbilla,
A. Nandi,
C. Strock,
K. W. Huff,
T. B. Rogers,
D. C. Johns,
P. D. Kessler,
and
C. P. Ordahl.
Cell-specific promoter in adenovirus vector for transgenic expression of SERCA1 ATPase in cardiac myocytes.
Am. J. Physiol.
274 (Cell Physiol. 43):
C645-C653,
1998
16.
Ji, Y.,
E. Loukianov,
T. Loukianova,
L. R. Jones,
and
M. Periasamy.
SERCA1a can functionally substitute for SERCA2a in the heart.
Am. J. Physiol.
276 (Heart Circ. Physiol. 45):
H89-H97,
1999
17.
Karin, N. J.,
Z. Kaprielian,
and
D. M. Fambrough.
Expression of avian Ca2+-ATPase in cultured mouse myogenic cells.
Mol. Cell. Biol.
9:
1978-1986,
1989
18.
Kariya, K.,
L. R. Karns,
and
P. C. Simpson.
Expression of a constitutively activated mutant of the beta-isozyme of protein kinase C in cardiac myocytes stimulates the promoter of the beta-myosin heavy chain isogene.
J. Biol. Chem.
266:
10023-10026,
1991
19.
Kimura, Y.,
M. Inui,
M. Kadoma,
Y. Kijima,
T. Sasaki,
and
M. Tada.
Effects of monoclonal antibody against phospholamban on calcium pump ATPase of cardiac sarcoplasmic reticulum.
J. Mol. Cell. Cardiol.
23:
1223-1230,
1991[Medline].
20.
Laemmli, U. K.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
227:
680-685,
1970[Medline].
21.
Lanzetta, P. A.,
L. J. Alvarez,
P. S. Reinsch,
and
O. A. Candia.
An improved assay for nanomole amounts of inorganic phosphate.
Anal. Biochem.
100:
95-97,
1979[Medline].
22.
Loukianov, E.,
Y. Ji,
I. L. Grupp,
D. L. Kirkpatrick,
D. L. Baker,
T. Loukianova,
G. Grupp,
J. Lytton,
R. A. Walsh,
and
M. Periasamy.
Enhanced myocardial contractility and increased Ca2+ transport function in transgenic hearts expressing the fast-twitch skeletal muscle sarcoplasmic reticulum Ca2+-ATPase.
Circ. Res.
83:
889-897,
1998
23.
MacLennan, D. H.,
C. J. Brandl,
B. Korczak,
and
N. M. Green.
Amino-acid sequence of a Ca2++Mg2+ dependent ATPase from rabbit muscle sarcoplasmic reticulum, deduced from its complementary DNA sequence.
Nature
316:
696-700,
1985[Medline].
24.
Mar, J. H.,
P. B. Antin,
T. A. Cooper,
and
C. P. Ordahl.
Analysis of the upstream regions governing expression of the chicken cardiac troponin T gene in embryonic cardiac and skeletal muscle cells.
J. Cell Biol.
107:
573-585,
1988
25.
Maruyama, K.,
and
D. H. MacLennan.
Mutation of aspartic acid-35, lysine-352 and lysine-515 alters the Ca2+ transport activity of the Ca2+-ATPase expressed in COS-1 cells.
Proc. Natl. Acad. Sci. USA
85:
3314-3318,
1988
26.
Morgan, J. P.,
R. E. Erny,
P. D. Allen,
W. Grossman,
and
J. K. Gwathmey.
Abnormal intracellular calcium handling, a major cause of systolic and diastolic dysfunction in ventricular myocadium from patients with heart failure.
Circulation
81, Suppl. 2:
III21-III32,
1990.
27.
Morris, G. L.,
H. C. Cheng,
J. Colyer,
and
J. H. Wang.
Phospholamban regulation of cardiac sarcoplasmic reticulum (Ca2+ + Mg2+)-ATPase. Mechanism of regulation and site of monoclonal antibody interaction.
J. Biol. Chem.
266:
11270-11275,
1991
28.
Schmidt, U.,
R. J. Hajjar,
P. A. Helm,
C. S. Kim,
A. A. Doye,
and
J. K. Gwathmey.
Contribution of abnormal sarcoplasmic reticulum ATPase activity to systolic and diastolic dysfunction in human heart failure.
J. Mol. Cell. Cardiol.
30:
1929-1937,
1998[Medline].
29.
Sham, J. S.,
L. R. Jones,
and
M. Morad.
Phospholamban mediates the
-adrenergic-enhanced Ca2+ uptake in mammalian ventricular myocytes.
Am. J. Physiol.
261 (Heart Circ. Physiol. 30):
H1344-H1349,
1991
30.
Strock, C.,
M. Cavagna,
W. Peiffer,
C. Sumbilla,
D. Lewis,
and
G. Inesi.
Direct demonstration of Ca2+ binding defects in sarco-endoplasmic reticulum Ca2+ ATPase mutants overexpressed in COS-1 cells transfected with adenovirus vectors.
J. Biol. Chem.
273:
15104-15109,
1998
31.
Sumbilla, C.,
L. Lu,
G. Inesi,
T. Ishii,
K. Takeyasu,
Y. Fang,
and
D. M. Fambrough.
Ca2+ dependent and thapsigargin-inhibited phosphorylation of Na+,K+-ATPase catalytic domain following chimeric recombination with the Ca+2-ATPase.
J. Biol. Chem.
268:
21185-21192,
1993
32.
Tada, M.,
M. Yamada,
M. Kadoma,
M. Inui,
and
F. Ohmori.
Calcium transport by cardiac sarcoplasmic reticulum and phosphorylation of phospholamban.
Mol. Cell. Biochem.
46:
73-95,
1982[Medline].
33.
Toyofuku, T.,
K. Kurzydlowski,
J. Lytton,
and
D. H. MacLennan.
The nucleotide binding/hinge domain plays a crucial role in determining isoform-specific Ca2+ dependence of organellar Ca2+-ATPases.
J. Biol. Chem.
267:
14490-14496,
1992
34.
Weber, K.,
and
M. Osborn.
The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.
J. Biol. Chem.
244:
4406-4417,
1969
35.
Zarain-Herzberg, A.,
D. H. MacLennan,
and
M. Periasamy.
Characterization of rabbit cardiac sarco(endo)plasmic reticulum Ca2+-ATPase gene.
J. Biol. Chem.
265:
4670-4677,
1990
This article has been cited by other articles:
![]() |
J. M. O'Donnell, A. Fields, X. Xu, S. A. K. Chowdhury, D. L. Geenen, and J. Bi Limited functional and metabolic improvements in hypertrophic and healthy rat heart overexpressing the skeletal muscle isoform of SERCA1 by adenoviral gene transfer in vivo Am J Physiol Heart Circ Physiol, December 1, 2008; 295(6): H2483 - H2494. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Smith Matters of the heart: the physiology of cardiac function and failure Exp Physiol, November 1, 2007; 92(6): 973 - 986. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. H. Talukder, A. Kalyanasundaram, X. Zhao, L. Zuo, P. Bhupathy, G. J. Babu, A. J. Cardounel, M. Periasamy, and J. L. Zweier Expression of SERCA isoform with faster Ca2+ transport properties improves postischemic cardiac function and Ca2+ handling and decreases myocardial infarction Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2418 - H2428. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Prasad, H. Ma, C. Sumbilla, D. I. Lee, M. G. Klein, and G. Inesi Phenylephrine hypertrophy, Ca2+-ATPase (SERCA2), and Ca2+ signaling in neonatal rat cardiac myocytes Am J Physiol Cell Physiol, June 1, 2007; 292(6): C2269 - C2275. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Hiranandani, T. Bupha-Intr, and P. M. L. Janssen SERCA overexpression reduces hydroxyl radical injury in murine myocardium Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H3130 - H3135. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Suarez, B. Gloss, D. D. Belke, Y. Hu, B. Scott, T. Dieterle, Y.-K. Kim, M. L. Valencik, J. A. McDonald, and W. H. Dillmann Doxycycline inducible expression of SERCA2a improves calcium handling and reverts cardiac dysfunction in pressure overload-induced cardiac hypertrophy Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H2164 - H2172. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ma, C. M. Sumbilla, I. K. G. Farrance, M. G. Klein, and G. Inesi Cell-specific expression of SERCA, the exogenous Ca2+ transport ATPase, in cardiac myocytes Am J Physiol Cell Physiol, March 1, 2004; 286(3): C556 - C564. [Abstract] [Full Text] |
||||
![]() |
S. Huke, V. Prasad, M. L. Nieman, K. J. Nattamai, I. L. Grupp, J. N. Lorenz, and M. Periasamy Altered dose response to beta -agonists in SERCA1a-expressing hearts ex vivo and in vivo Am J Physiol Heart Circ Physiol, September 1, 2002; 283(3): H958 - H965. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. del Monte, R. J. Hajjar, S. E. Harding, and G. Inesi Overwhelming Evidence of the Beneficial Effects |